**Specifications Table**TableSubject area*Genomics*More specific subject area*Peroxisomal Disorders*Type of data[Table 1](#t0005){ref-type="table"}*-- Biochemical analytes*[Table 2](#t0010){ref-type="table"} -- *Variants from exome sequencing*[Fig. 1](#f0005){ref-type="fig"} -- *Clinical timeline and diagnostic workup*[Fig. 2](#f0010){ref-type="fig"}*-- Biochemical analytes*How data was acquired*Blood samples and a skin biopsy were obtained from the patient. DNA, plasma and cultured fibroblasts were analyzed in the context of the patient's diagnostic course. LC--MS/MS, Enzyme activity using radioactive substrates, colorimetric assays, next-generation sequencing.*Data format*Analyzed datasets, Excel, Tif files.*Experimental factors*Unique genotype* (*n=1*)Experimental features*Plasma samples and cultured fibroblast from a skin biopsy were used for peroxisomal biochemical analysis. Genomic DNA was utilized for whole-exome sequencing.*Data source location*Houston Texas*Data accessibility*Date is included with this article*

**Value of the data**•A profile of a patient with an atypical peroxisomal biogenesis disorder which can be compared with other patient׳s with these phenotypes.•Clinical review of diagnostic considerations for atypical peroxisomal biogenesis disorders.•Comprehensive set of functional consequences of F332del allele of *PEX16*.

1. Data {#s0005}
=======

See [Table 1](#t0005){ref-type="table"}.

1.Plasma VLCFA -- plasma was collected at ages 10 years, 11 years and 22 years for VLCFA analysis. Values shown in ug/ml. C24/C22 and C26/C22 ratios shown. Z-scores of the patient׳s sample measurment as compared to a set of normal controls shown.2.Fibroblast VLCFA -- patient fibroblasts were cultured and analyzed for VLCFA analysis. Values shown are in µg/mg protein. Z-scores of the patient׳s sample measurment as compared to a set of normal controls shown.3.Catalase Distribution -- cultured cells were analyzed for Catalase Distribution (expressed in % soluble). A Z-score of the patient׳s sample is shown.4.Plasmalogen synthesis assay from radiolabel enzyme assay is shown.5.Plasma pipecolic acid (expressed in µmole/L).6.Lyso-PC -- LC MS/MS of lysophospholipids for the patient׳s blood sample at 22 years.7.14C oxidation assays for Phytanic and Pristanic acid (in % of the mean of controls) shown.List of variants in disease-causing genes including heterozygous and homozygous variants which were verified by Sanger sequencing. The Gene, position, specific isoform, nucleotide, protein change (predicted), and zygosity are shown. AR=Autosomal recessive. Comments contain segregation information from the parents or other populations ([Table 2](#t0010){ref-type="table"}). A clinical and diagnostic timeline for the patient showing clinical events and gene diagnostic tests. WES=Whole-exome sequencing ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}).

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Ethics statement {#s0015}
---------------------

Informed consent for the research and for publication was obtained prior to participation for the subject who was recruited under an Institutional Review Board approved protocol at Baylor College of Medicine.

2.2. Peroxisomal biochemical studies {#s0020}
------------------------------------

Plasma samples and cultured fibroblast from a skin biopsy were used for peroxisomal biochemical analysis.--Plasma pipecolic acid was measured by electron capture negative ion mass fragmentography [@bib1].--Very-long-chain fatty acid levels and total lipid fatty acid profile were measured as described [@bib2], [@bib3].--The plasmalogen assay was performed using C14 radioactivity incorporation and H3 counts to measure microsomal plasmalogen steps [@bib4].--Fibroblast oxidation assays were performed using radioactive substrates to assay enzyme activity [@bib5], [@bib6].--Measurement of C26:0-lyso-PC was performed as described [@bib7] and bile acid quantitation was performed by tandem mass spectrometry [@bib8].--Catalase distribution in cultured cells was performed and quantified (% soluble catalase) [@bib9], [@bib10].

2.3. Whole-exome capture, sequencing and data analysis {#s0025}
------------------------------------------------------

The patient underwent WES through the Whole Genome Laboratory (<https://www.bcm.edu/research/medical-genetics-labs/index.cfm?PMID=21319>) using methods described [@bib11].--Produced sequence reads were aligned to the GRCh37 (hg19) human genome reference assembly using the HGSC Mercury analysis pipeline (<http://www.tinyurl.com/HGSC-Mercury/>). Variants were determined and called using the Atlas2 [@bib12] suite to produce a variant call file (VCF [@bib13]).--High-quality variants were annotated using an in-house developed suite of annotation tools [@bib14].

Appendix A. Supplementary material {#s0035}
==================================
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Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2015.12.011](http://dx.doi.org/10.1016/j.dib.2015.12.011){#ir0015}.

![Clinical timeline for the patient.](gr1){#f0005}

![Peroxisomal biochemical studies. (A) C26:0 Lyso PC measured by LC--MS--MS for the Patient׳s plasma compared to Normals and other disease populations. (B) Catalase Distributionin cultured fibroblasts (expressed as % soluble). (C) Bile acid measurements in pmoles/10µl plasma for the Patient, controls and other disease populations.](gr2){#f0010}

###### 

Comprehensive plasma and fibroblast biochemical analysis.

Table 1

  **Analyte**                                          **Control fibroblasts**   **Zellweger syndrome**   **Patient\@22 years**
  ---------------------------------------------------- ------------------------- ------------------------ -----------------------
  Phytanic acid oxidation (% mean of control value)    100                       5.7                      73
  Pristanic acid oxication (% mean of control Value)   100                       4.9                      156.9

###### 

Candidate variants table from Whole-exome sequencing.

Table 2

  **Gene**   **Postion**      **Isoform**   **Nucleotide**    **Protein**   **Zygosity**   **Disease**                                                    **Disease inheritance**   **Comment**
  ---------- ---------------- ------------- ----------------- ------------- -------------- -------------------------------------------------------------- ------------------------- ---------------------------------------------
  CTC1       Ch17:8134658     NM_025099     c.2605C\>T        p.Q869X       Het            Cerebroretinal microangiopathy with calcifications and cysts   AR                        Father also heterozygous
  SYNE1      Chr6:152730222   NM_033071     c.6542C\>T        p.T2181I      Het            Spinocerebellar ataxia, autosomal recessive 8                  AR                        Mother also heterozygous
  C5orf42    Chr5: 37185062   NM_023073     c.4309A\>G        p.I1437V      Het            Joubert syndrome                                               AR                        Novel variant
  CLN3       CH16:28493901    uc010vcx.1    c.583C\>G         p.P195A       Het            Ceroid lipofuscinosis                                          AR                        rs146839771
  VPS13A     Chr9:79902873    NM_033305     c.3356G\>A        p.G1119E      Het            Choreoacanthocytosis                                           AR                        rs144358567
  PSAP       Ch10:73588801    NM_002778     c.409C\>G         p.L137V       Het            Combined SAP deficiency                                        AR                        Novel variant
  MAN1B1     Ch9: 140002934   NM_016219     c.1991C\>T        p.T664M       Het            Mental retardation, autosomal recessive 15                     AR                        Reported in ESP5400 and or Thousand Genomes
  NPC1       Chr18:21166261   NM_000271     c.47G\>A          p.C16Y        Het            Niemann--Pick disease, type D                                  AR                        Novel variant
  BRAT1      Chr7:2579447     NM_152743     c.1471G\>A        p.G491S       Het            Rigidity and multifocal seizure syndrome, lethal neonatal      AR                        Father also heterozygous
  BRAT1      Chr7: 2582935    NM_152743     c.826G\>A         p.D276N       Het            Rigidity and multifocal seizure syndrome, lethal neonatal      AR                        Mother heterozygous, rs146546197
  PEX16      Chr11:45931818   NM_004813     c.995_997delTCT   p.F332del     Hom            Zellweger syndrome, complementation 9                          AR                        Novel variant, both parents heterozygous
